Amgen Inc. (NASDAQ:AMGN) Shares Acquired by Sawyer & Company Inc

Sawyer & Company Inc boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.4% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,996 shares of the medical research company’s stock after buying an additional 57 shares during the quarter. Amgen accounts for approximately 1.5% of Sawyer & Company Inc’s investment portfolio, making the stock its 23rd largest position. Sawyer & Company Inc’s holdings in Amgen were worth $4,169,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of AMGN. Capital Performance Advisors LLP bought a new stake in shares of Amgen during the 3rd quarter worth $25,000. Legacy Investment Solutions LLC acquired a new position in shares of Amgen in the 3rd quarter valued at $29,000. Hershey Financial Advisers LLC purchased a new position in Amgen in the 2nd quarter worth about $30,000. Matrix Trust Co acquired a new stake in Amgen during the 3rd quarter worth about $36,000. Finally, Livelsberger Financial Advisory purchased a new stake in Amgen during the third quarter valued at about $56,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Trading Up 0.7 %

Amgen stock opened at $268.94 on Thursday. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85. The company’s fifty day moving average price is $277.12 and its two-hundred day moving average price is $308.03. The company has a market capitalization of $144.56 billion, a price-to-earnings ratio of 34.44, a PEG ratio of 2.91 and a beta of 0.56. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm’s revenue was up 23.2% compared to the same quarter last year. During the same period last year, the business earned $4.96 EPS. On average, analysts forecast that Amgen Inc. will post 19.53 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.54%. This is a boost from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s payout ratio is presently 121.90%.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $405.00 target price on shares of Amgen in a research report on Tuesday, October 22nd. Royal Bank of Canada cut their target price on shares of Amgen from $360.00 to $330.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 27th. Citigroup reduced their target price on Amgen from $335.00 to $310.00 in a report on Wednesday, November 27th. UBS Group lowered their price target on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday, October 31st. Finally, TD Cowen increased their price objective on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $314.91.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.